多囊卵巢综合征(PCOS),这在育龄妇女中很常见,以低度慢性炎症为特征,并与一些健康问题和生态失调有关。开菲尔已被证明有许多有益的健康影响;然而,其对PCOS的影响尚不清楚。本研究旨在研究开菲尔对PCOS肠道菌群和健康结果的影响。在这项干预研究中,17名患有PCOS的女性每天消耗250毫升的开菲尔(含有乳杆菌的开菲尔亚种。kefiranofaciens,柯氏乳杆菌亚种。kefirgranum,Kefiri乳杆菌,嗜酸乳杆菌,帕克菲里乳酸杆菌,保加利亚乳杆菌,罗伊氏乳杆菌,干酪乳杆菌,发酵乳杆菌,瑞士乳杆菌,乳酸乳球菌,间期明串珠菌,双歧杆菌,嗜热链球菌,马尔克斯克鲁维酵母,乳酸克鲁维酵母,巴氏醋杆菌,和酿酒酵母)持续8周。食物消耗和身体活动记录,人体测量,生活质量,在研究开始和结束时采集粪便和血液样本。在开菲尔干预后,心理健康(分别为58.8±15.08;64.0±15.23)和身体功能(分别为95.00和1020)类别的生活质量显着提高(p<0.05)。此外,白细胞介素-6(IL-6),炎性细胞因子之一,显着降低(174.00和109.10ng/L,分别)(p<0.05)。用zonulin评估肠屏障通透性,没有观察到明显的变化。肠道菌群分析表明,尽管芽孢杆菌属和乳球菌属的相对丰度显着增加,荷尔曼尼亚属随着开菲尔消费量的增加而减少(p<.05)。总之,开菲尔似乎有利于改善微生物群和一些健康结果,如减少炎症和改善PCOS的生活质量。因此,开菲尔可用于治疗PCOS。
Polycystic Ovary Syndrome (PCOS), which is common among women of reproductive age, is characterized by low-grade chronic inflammation and is associated with several health problems and dysbiosis.
Kefir has been shown to have many beneficial health effects; however, its effect on PCOS is unknown. This study aimed to examine the effect of
kefir on the intestinal microbiota and health outcomes in PCOS. In this intervention study, 17 women with PCOS consumed 250 mL/day of
kefir (containing Lactobacillus kefiranofaciens subsp. kefiranofaciens, Lactobacillus kefiranofaciens subsp. kefirgranum, Lactobacillus kefiri, Lactobacillus acidophilus, Lactobacillus parakefiri, Lactobacillus bulgaricus, Lactobacillus reuteri, Lactobacillus casei, Lactobacillus fermentum, Lactobacillus helveticus, Lactococcus lactis, Leuconostoc mesentereoides, Bifidobacterium bifidum, Streptococcus thermophilus, Kluyveromyces marxianus, Kluyveromyces lactis, Acetobacter pasteurianus, and Saccharomyces cerevisiae) for 8 weeks. Food consumption and physical activity records, anthropometrical measurements, quality of life, and fecal and blood samples were taken at the study\'s beginning and end. Quality of life in mental health (58.8 ± 15.08; 64.0 ± 15.23, respectively) and physical function (95.00 and 100.00, respectively) categories showed a significant increase after kefir intervention (p < .05). Additionally, Interleukin-6 (IL-6), one of the inflammatory cytokines, significantly decreased (174.00 and 109.10 ng/L, respectively) (p < .05). The intestinal barrier permeability was evaluated with zonulin, and no significant change was observed. Gut microbiota analysis showed that while the relative abundance of the class Bacilli and genus Lactococcus significantly increased, the genus Holdemania decreased with kefir consumption (p < .05). In conclusion,
kefir appears to be beneficial for improving the microbiota and some health outcomes, like reducing inflammation and improving quality of life in PCOS. Therefore,
kefir may be useful in the treatment of PCOS.